Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Average Target Price from Brokerages

Shares of Nkarta, Inc. (NASDAQ:NKTX) have been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $15.00.

Several analysts recently issued reports on the company. Needham & Company LLC decreased their target price on Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. RODMAN&RENSHAW raised shares of Nkarta to a “strong-buy” rating in a report on Wednesday, October 9th. HC Wainwright cut their target price on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Rodman & Renshaw initiated coverage on shares of Nkarta in a report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price objective for the company. Finally, Mizuho reduced their target price on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a report on Thursday, November 21st.

Institutional Trading of Nkarta

Several hedge funds have recently made changes to their positions in NKTX. Meeder Asset Management Inc. bought a new stake in Nkarta during the second quarter worth approximately $26,000. Erste Asset Management GmbH purchased a new stake in Nkarta during the 3rd quarter valued at $33,000. GAMMA Investing LLC lifted its position in Nkarta by 110.9% in the third quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock worth $45,000 after buying an additional 5,243 shares during the last quarter. Forefront Analytics LLC purchased a new position in Nkarta during the second quarter worth $70,000. Finally, Intech Investment Management LLC bought a new position in Nkarta during the third quarter valued at $74,000. 80.54% of the stock is currently owned by hedge funds and other institutional investors.

Nkarta Stock Down 0.4 %

NASDAQ:NKTX opened at $2.41 on Monday. The business’s 50-day simple moving average is $2.84 and its two-hundred day simple moving average is $4.51. Nkarta has a 52 week low of $2.08 and a 52 week high of $16.24. The stock has a market cap of $170.07 million, a PE ratio of -1.28 and a beta of 0.82.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.